TY - JOUR
T1 - Sertraline inhibits the transport of PAT1 substrates in vivo and in vitro
AU - Nielsen, Carsten Uhd
AU - Frølund, Sidsel Balsgaard
AU - Abdulhadi, S
AU - Sari, H
AU - Langthaler, L
AU - Nøhr, Mark Klitgaard
AU - Kall, M A
AU - Brodin, B
AU - Holm, R
N1 - © 2013 The British Pharmacological Society.
PY - 2013/11
Y1 - 2013/11
N2 - Background and Purpose Intestinal nutrient transporters may mediate the uptake of drugs. The aim of this study was to investigate whether sertraline interacts with the intestinal proton-coupled amino acid transporter 1 PAT1 (SLC36A1). Experimental Approach In vitro investigations of interactions between sertraline and human (h)PAT1, hSGLT1 (sodium-glucose linked transporter 1) and hPepT1 (proton-coupled di-/tri-peptide transporter 1) were conducted in Caco-2 cells using radiolabelled substrates. In vivo pharmacokinetic investigations were conducted in male Sprague-Dawley rats using gaboxadol (10 mg·kg -1, p.o.) as a PAT1 substrate and sertraline (0-30.6 mg·kg-1). Gaboxadol was quantified by hydrophilic interaction chromatography followed by MS/MS detection. Key Results Sertraline inhibited hPAT1-mediated L-[3H]-Pro uptake in Caco-2 cells. This interaction between sertraline and PAT1 appeared to be non-competitive. The uptake of the hSGLT1 substrate [14C]-α-methyl-D-glycopyranoside and the hPepT1 substrate [14C]-Gly-Sar in Caco-2 cells was also decreased in the presence of 0.3 mM sertraline. In rats, the administration of sertraline (0.1-10 mM, corresponding to 0.3-30.6 mg·kg-1, p.o.) significantly reduced the maximal gaboxadol plasma concentration and AUC after its administration p.o. Conclusions and Implications Sertraline is an apparent non-competitive inhibitor of hPAT1-mediated transport in vitro. This inhibitory effect of sertraline is not specific to hPAT1 as substrate transport via hPepT1 and hSGLT1 was also reduced in the presence of sertraline. In vivo, sertraline reduced the amount of gaboxadol absorbed, suggesting that the inhibitory effect of sertraline on PAT1 occurs both in vitro and in vivo. Hence, sertraline could alter the bioavailability of drugs absorbed via PAT1.
AB - Background and Purpose Intestinal nutrient transporters may mediate the uptake of drugs. The aim of this study was to investigate whether sertraline interacts with the intestinal proton-coupled amino acid transporter 1 PAT1 (SLC36A1). Experimental Approach In vitro investigations of interactions between sertraline and human (h)PAT1, hSGLT1 (sodium-glucose linked transporter 1) and hPepT1 (proton-coupled di-/tri-peptide transporter 1) were conducted in Caco-2 cells using radiolabelled substrates. In vivo pharmacokinetic investigations were conducted in male Sprague-Dawley rats using gaboxadol (10 mg·kg -1, p.o.) as a PAT1 substrate and sertraline (0-30.6 mg·kg-1). Gaboxadol was quantified by hydrophilic interaction chromatography followed by MS/MS detection. Key Results Sertraline inhibited hPAT1-mediated L-[3H]-Pro uptake in Caco-2 cells. This interaction between sertraline and PAT1 appeared to be non-competitive. The uptake of the hSGLT1 substrate [14C]-α-methyl-D-glycopyranoside and the hPepT1 substrate [14C]-Gly-Sar in Caco-2 cells was also decreased in the presence of 0.3 mM sertraline. In rats, the administration of sertraline (0.1-10 mM, corresponding to 0.3-30.6 mg·kg-1, p.o.) significantly reduced the maximal gaboxadol plasma concentration and AUC after its administration p.o. Conclusions and Implications Sertraline is an apparent non-competitive inhibitor of hPAT1-mediated transport in vitro. This inhibitory effect of sertraline is not specific to hPAT1 as substrate transport via hPepT1 and hSGLT1 was also reduced in the presence of sertraline. In vivo, sertraline reduced the amount of gaboxadol absorbed, suggesting that the inhibitory effect of sertraline on PAT1 occurs both in vitro and in vivo. Hence, sertraline could alter the bioavailability of drugs absorbed via PAT1.
U2 - 10.1111/bph.12341
DO - 10.1111/bph.12341
M3 - Journal article
C2 - 23962042
SN - 0007-1188
VL - 170
SP - 1041
EP - 1052
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 5
ER -